Intellia Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR technology. Its core products include NTLA-2001, aimed at treating transthyretin amyloidosis, and NTLA-2002 for treating hereditary angioedema. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. Intellia is positioned as a niche player in the biotech industry.
The investment profile of Intellia Therapeutics is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue generation. The company currently does not offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon to assess the development of its pipeline.
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-11 05:23 | Mantener | Vender | scenario_deterioration |
| 2026-06-05 02:44 | Vender | Mantener | Weak fundamentals offset by recent positive momentum. |
| 2026-05-28 02:53 | Mantener | Vender | Weak fundamentals with recent positive momentum. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-05-13 10:28 | Bernstein | Objetivo aumentado | 13 → 17 | 13.99 |
| 2026-05-12 10:42 | Canaccord Genuity | Objetivo reducido | 58 → 49 | 14.42 |
| 2026-04-27 17:56 | Chardan Capital | Objetivo aumentado | 27 → 30 | 13.03 |
